ArticleBioMed research international2021
Prevalence of CTX-M
Article in BioMed research international, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 20 citations in OpenAlex.
- Prevalence and molecular characterization of ESBL-producing Enterobacterales in clinical samples from the Boucle du Mouhoun region in Burkina Faso.BMC infectious diseases · 2026Article
- High prevalence and co-existence of SHV and CTX-M genes in extensively drug-resistant (XDR) Gram-negative bacteria isolated from hospital settings in Faisalabad District, Pakistan.Molecular biology reports · 2026Article
- Genetic diversity of ESBL-producingBioinformation · 2026Article
- Detection of AcrAB efflux pump mediated ciprofloxacin resistance in Escherichia coli and Klebsiella pneumoniae in Nepal.BMC infectious diseases · 2025Article
- Carbapenemase and extended-spectrum β-lactamase producing bacteria isolated from municipal wastewater treatment plant and urban river in Nepal.Current research in microbial sciences · 2025Article
- Prevalence ofThe Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale · 2024Article
- Phenotypic and Genotypic Characterization of Extended Spectrum Beta-Lactamase-Producing Clinical Isolates ofInternational journal of microbiology · 2024Article
- Phenotypic and genotypic characterization of multidrug resistant and extended-spectrum β-lactamase-producing Enterobacterales isolated from clinical samples in the western region in Cameroon.BMC infectious diseases · 2023Article
- Gut colonization and subsequent infection of neonates caused by extended-spectrum beta-lactamase-producingFrontiers in cellular and infection microbiology · 2023Article
- Phylogeny and antimicrobial resistance of extended-spectrum beta-lactamaseproducing Escherichia coli from hospitalized oncology patients in PerúBiomedica : revista del Instituto Nacional de Salud · 2022Article
- GLO1 Contributes to the Drug Resistance ofInfection and drug resistance · 2022Article
- Prevalence of Multidrug-ResistantJournal of tropical medicine · 2022Review
- Prevalence of carbapenemase-producing Klebsiella pneumoniae at a tertiary care hospital in Kathmandu, Nepal.Tropical medicine and health · 2021Article
- Clinical Specimens are the Pool of Multidrug- resistant Pseudomonas aeruginosa Harbouring oprL and toxA Virulence Genes: Findings from a Tertiary Hospital of Nepal.Emergency medicine international · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The emergence of multidrug resistant (MDR) bacteria which is attributable to extended spectrum
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.